The FDA has started a priority review of Vertex Pharma and CRISPR Therapeutics’ exagamglogene autotemcel (exa-cel) in sickle cell disease (SCD), with a decision on approval due by 8th December.

A gene-editing drug developed by CRISPR Therapeutics and Vertex Pharma has continued ... and SCD who had been treated with CTX001 (exagamglogene autotemcel or exa-cel) for between around 2 and ...

The approval of the first CRISPR-based therapy in late 2023—CRISPR Therapeutics and Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel or exa-cel) for sickle cell disease and β ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that its Chief Operating Officer, Julianne ...

Concurrent with Lyfgenia’s approval, the FDA approved Vertex and CRISPR Therapeutics’ CRSP exagamglogene autotemcel, a CRISPR/Cas9 genome-edited cell therapy, for the treatment of SCD in ...

The company has a commercial arrangement. This makes exagamglogene autotemcel available to the NHS with a discount. The size of the discount is commercial in confidence.

Casgevy, developed by Vertex Pharmaceuticals and CRISPR Therapeutics ... CRISPR-based gene-editing therapy, Casgevy (exagamglogene autotemcel), to sickle cell disorder and beta thalassaemia ...

In 2024, BOC received Vertex accreditation for its bone marrow transplant and cellular therapy services, enabling it to provide, as an accredited centre of excellence, CRISPR-based gene-editing ...